Login to Your Account



Gilead's Quad Non-Inferior to Atripla; Analysts Await Details

By Trista Morrison


Tuesday, August 16, 2011
Days after winning FDA approval of Complera – a.k.a. Btripla, the follow-on to HIV blockbuster Atripla – Gilead Sciences Inc. unveiled the first Phase III data with the drug that's expected to blow them both out of the water: Quad.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription